Pacific Excel Wealth Advisors Inc. Purchases Shares of 1,785 Stryker Corporation $SYK

Pacific Excel Wealth Advisors Inc. acquired a new position in Stryker Corporation (NYSE:SYK) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 1,785 shares of the medical technology company’s stock, valued at approximately $562,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. jvl associates llc lifted its stake in Stryker by 176.1% during the 2nd quarter. jvl associates llc now owns 1,944 shares of the medical technology company’s stock valued at $612,000 after acquiring an additional 1,240 shares during the period. Bangor Savings Bank increased its stake in shares of Stryker by 4.7% in the second quarter. Bangor Savings Bank now owns 5,458 shares of the medical technology company’s stock worth $1,718,000 after acquiring an additional 245 shares during the period. Stonebridge Financial Group LLC raised its holdings in shares of Stryker by 16.2% during the second quarter. Stonebridge Financial Group LLC now owns 16,134 shares of the medical technology company’s stock worth $5,079,000 after purchasing an additional 2,251 shares during the last quarter. Confluence Investment Management LLC lifted its position in Stryker by 1.9% during the second quarter. Confluence Investment Management LLC now owns 212,000 shares of the medical technology company’s stock valued at $66,746,000 after purchasing an additional 3,941 shares during the period. Finally, First Financial Bank Trust Division boosted its holdings in Stryker by 2.1% in the second quarter. First Financial Bank Trust Division now owns 35,165 shares of the medical technology company’s stock valued at $11,071,000 after purchasing an additional 724 shares during the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the company. Raymond James Financial set a $370.00 price objective on Stryker in a research note on Friday. BMO Capital Markets started coverage on Stryker in a report on Wednesday, July 8th. They set an “outperform” rating and a $369.00 target price on the stock. Evercore set a $350.00 price target on Stryker in a research report on Monday, July 6th. Citigroup reissued an “outperform” rating on shares of Stryker in a report on Monday. Finally, Deutsche Bank Aktiengesellschaft set a $315.00 price objective on Stryker in a research report on Friday, May 1st. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $386.28.

Insider Transactions at Stryker

In other news, VP M Kathryn Fink sold 5,220 shares of the stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $283.85, for a total transaction of $1,481,697.00. Following the transaction, the vice president owned 13,137 shares in the company, valued at $3,728,937.45. This trade represents a 28.44% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Robert S. Fletcher sold 4,544 shares of Stryker stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the completion of the sale, the vice president directly owned 10,582 shares in the company, valued at $3,247,298.34. This represents a 30.04% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 323,264 shares of company stock valued at $100,659,489 in the last three months. 4.60% of the stock is currently owned by company insiders.

Stryker Trading Down 1.5%

SYK stock opened at $336.08 on Wednesday. Stryker Corporation has a 52-week low of $281.00 and a 52-week high of $396.86. The company has a quick ratio of 1.33, a current ratio of 2.16 and a debt-to-equity ratio of 0.59. The firm has a market cap of $128.84 billion, a P/E ratio of 34.83, a PEG ratio of 2.17 and a beta of 0.76. The company’s 50-day simple moving average is $318.23 and its 200-day simple moving average is $334.46.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, beating the consensus estimate of $3.49 by $0.20. The firm had revenue of $6.59 billion during the quarter, compared to analyst estimates of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.Stryker’s revenue for the quarter was up 9.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, equities analysts forecast that Stryker Corporation will post 15.03 EPS for the current fiscal year.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.